Progressive diastolic dysfunction in survivors of pediatric differentiated thyroid carcinoma.


Journal

European journal of endocrinology
ISSN: 1479-683X
Titre abrégé: Eur J Endocrinol
Pays: England
ID NLM: 9423848

Informations de publication

Date de publication:
01 Oct 2022
Historique:
received: 10 02 2022
accepted: 10 08 2022
pubmed: 11 8 2022
medline: 15 9 2022
entrez: 10 8 2022
Statut: epublish

Résumé

Pediatric differentiated thyroid cancer (DTC) has an excellent prognosis but unknown late effects of treatment. The initial cardiac evaluation showed subclinical diastolic dysfunction in 20% of adult survivors. The objective of this follow-up study was to determine the clinical course of this finding. This multicenter study, conducted between 2018 and 2020, re-evaluated survivors after 5 years. The primary endpoint was echocardiographic diastolic cardiac function (depicted by the mean of the early diastolic septal and early diastolic lateral tissue velocity (e' mean)). Secondary endpoints were other echocardiographic parameters and plasma biomarkers. Follow-up evaluation was completed in 47 (71.2%) of 66 survivors who had completed their initial evaluation. Of these 47 survivors, 87.2% were women. The median age was 39.8 years (range: 18.8-60.3), and the median follow-up after the initial diagnosis was 23.4 years (range: 10.2-48.8). Between the first and second evaluation, the e' mean significantly decreased by 2.1 cm/s (s.d. 2.3 cm/s, P < 0.001). The median left ventricular ejection fraction did not significantly change (58.0% vs 59.0%, P= NS). In the best explanatory model of e' mean, multivariate linear regression analysis showed that BMI and age were significantly associated with e' mean (β coefficient: -0.169, 95% CI: -0.292; -0.047, P = 0.008 and β coefficient: -0.177, 95% CI: -0.240; -0.113, P < 0.001, respectively). In these relatively young survivors of pediatric DTC, diastolic function decreased significantly during 5-year follow-up and is possibly more pronounced than in normal aging. This finding requires further follow-up to assess clinical consequences.

Sections du résumé

Background UNASSIGNED
Pediatric differentiated thyroid cancer (DTC) has an excellent prognosis but unknown late effects of treatment. The initial cardiac evaluation showed subclinical diastolic dysfunction in 20% of adult survivors. The objective of this follow-up study was to determine the clinical course of this finding.
Methods UNASSIGNED
This multicenter study, conducted between 2018 and 2020, re-evaluated survivors after 5 years. The primary endpoint was echocardiographic diastolic cardiac function (depicted by the mean of the early diastolic septal and early diastolic lateral tissue velocity (e' mean)). Secondary endpoints were other echocardiographic parameters and plasma biomarkers.
Results UNASSIGNED
Follow-up evaluation was completed in 47 (71.2%) of 66 survivors who had completed their initial evaluation. Of these 47 survivors, 87.2% were women. The median age was 39.8 years (range: 18.8-60.3), and the median follow-up after the initial diagnosis was 23.4 years (range: 10.2-48.8). Between the first and second evaluation, the e' mean significantly decreased by 2.1 cm/s (s.d. 2.3 cm/s, P < 0.001). The median left ventricular ejection fraction did not significantly change (58.0% vs 59.0%, P= NS). In the best explanatory model of e' mean, multivariate linear regression analysis showed that BMI and age were significantly associated with e' mean (β coefficient: -0.169, 95% CI: -0.292; -0.047, P = 0.008 and β coefficient: -0.177, 95% CI: -0.240; -0.113, P < 0.001, respectively).
Conclusions and relevance UNASSIGNED
In these relatively young survivors of pediatric DTC, diastolic function decreased significantly during 5-year follow-up and is possibly more pronounced than in normal aging. This finding requires further follow-up to assess clinical consequences.

Identifiants

pubmed: 35947635
doi: 10.1530/EJE-22-0094
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

497-505

Auteurs

Antoinette D Reichert (AD)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Internal Medicine, Groningen, the Netherlands.

Marloes Nies (M)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Internal Medicine, Groningen, the Netherlands.

Wim J E Tissing (WJE)

University of Groningen, Beatrix Children's Hospital, Paediatric Oncology, University Medical Center Groningen, Groningen, Groningen.
Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.

Anneke C Muller Kobold (AC)

Department of Laboratory Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Mariëlle S Klein Hesselink (MS)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Internal Medicine, Groningen, the Netherlands.

Adrienne H Brouwers (AH)

Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Bas Havekes (B)

Division of Endocrinology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, the Netherlands.

Marry M van den Heuvel-Eibrink (MM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Department of Pediatric Oncology, Sophia Children's Hospital, Erasmus Medical Center, Rotterdam, the Netherlands.

Helena J H van der Pal (HJH)

Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Amsterdam, the Netherlands.
Department of Medical Oncology, Academic Medical Center, Amsterdam UMC, Amsterdam, the Netherlands.

John T M Plukker (JTM)

Department of Surgical Oncology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Hanneke M van Santen (HM)

Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
Department of Pediatrics, Wilhelmina Children's Hospital, University Medical Center Utrecht, Utrecht, the Netherlands.

Eleonora P M Corssmit (EPM)

Leiden University Medical Center, Division of Endocrinology, Department of Internal Medicine, Leiden, the Netherlands.

Romana T Netea-Maier (RT)

Radboud University Medical Center, Division of Endocrinology, Department of Internal Medicine, Nijmegen, the Netherlands.

Robin P Peeters (RP)

Erasmus Medical Center, Department of Internal Medicine and Erasmus MC Academic Center for Thyroid Disease, Rotterdam, the Netherlands.

Eveline W C M van Dam (EWCM)

Department of Endocrinology, Internal Medicine, Amsterdam UMC, location VUmc, Amsterdam, The Netherlands.

Johannes G M Burgerhof (JGM)

Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Peter van der Meer (P)

Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.

Gianni Bocca (G)

University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Pediatric Endocrinology, Groningen, the Netherlands.

Thera P Links (TP)

Department of Endocrinology, University of Groningen, University Medical Center Groningen, Internal Medicine, Groningen, the Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH